Advanced search
Publication Cover
Expert Opinion on Drug Metabolism & Toxicology Volume 16, 2020 - Issue 7
Submit an article Journal homepage
98
Views
0
CrossRef citations to date
0
Altmetric
Original Research

Pharmacokinetic modeling to determine the minimum effective dose of disease-specific antibodies for preventing hepatitis A post-exposure

Megan K Younga School of Medicine and Menzies Health Institute – Queensland, Griffith University, Southport, Australia;b Metro North Public Health Unit, Metro North Hospital and Health Service, Brisbane, AustraliaCorrespondence[email protected]
View further author information
,
Shu-Kay Nga School of Medicine and Menzies Health Institute – Queensland, Griffith University, Southport, AustraliaView further author information
,
Graeme R Nimmoa School of Medicine and Menzies Health Institute – Queensland, Griffith University, Southport, Australia;c Pathology Queensland, Queensland Health, Brisbane, AustraliaView further author information
&
Allan W Crippsa School of Medicine and Menzies Health Institute – Queensland, Griffith University, Southport, AustraliaView further author information
Pages 641-644 | Received 05 Mar 2020, Accepted 28 Apr 2020, Published online: 03 May 2020

References

  • Communicable Diseases Network Australia. Hepatitis A: national guidelines for public health units. Canberra: Commonwealth Department of Health; 2018.
  • Liu J, Nikolova D, Fei Y. Immunoglobulins for preventing hepatitis A. Cochrane Database Syst Rev. 2009;(2). Art. No.: CD004181. DOI:10.1002/14651858.CD004181.pub2.
  • Australian Government Department of Health. Overweight and obesity Canberra: Australian government department of health; 2019 [updated 19 Jun 2019; cited 2019 Jun 2019]. Available from: https://www.health.gov.au/internet/main/publishing.nsf/Content/Overweight-and-Obesity
  • Young M. The indications and safety of polyvalent immunoglobulin for post-exposure prophylaxis of hepatitis A, rubella and measles. Hum Vaccines Immunother. 2019. DOI:10.1080/21645515.2019.1621148
  • Thakur A, Pedersen L, Jungersen G. Immune markers and correlates of protection for vaccine induced immune responses. Vaccine. 2012;30:4907–4920.
  • Plotkin S. Correlates of protection induced by vaccination. Clin Vaccin Immunol. 2010;17(7):1055–1065.
  • Mould G, Sutton J, Matejtschuk P, et al. Solvent/detergent treatment does not alter the tolerance or uptake of human normal immunoglobulin for intramuscular injection. Vox Sang. 2001;80:151–158.
  • European Department for the Quality of Medicines. European pharmacopoeia. 8th ed. Strasbourg, France: European Department for the Quality of Medicines, Council of Europe; 2014.
  • Young M, Ng S, Nimmo G, et al. The optimal dose of disease-specific antibodies for post-exposure prophylaxis of measles and rubella in Australia: new guidelines recommended. Expert Opin Drug Metab Toxicol. 2018;14(7):663–669.
  • Lemon S, Murphy P, Provost P, et al. Immunoprecipitation and virus neutralization assays demonstrate qualitative differences between protective antibody responses to inactivated hepatitis A vaccine and passive immunisation with immune globulin. J Infect Dis. 1997;176:9–19.
  • Dubois A, Bertrand J, Mentre F. Mathematical expressions of the pharmacokinetic and pharmacodynamic models implemented in the PFIM software. Paris: University Paris Diderot; 2011.
  • DiaSorin. ETI-AB-HAVK PLUS [instructions for use]; 2004.
  • bioMerieux SA. VIDAS Anti-HAV Total [instructions for use]; 2016.
  • Lobo E, Hansen R, JP B. Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci. 2004;93(11):2645–2668.
  • Nelson N. Updated dosing instructions for immune globulin (Human) GamaSTAN S/D for hepatitis a virus prophylaxis. MMWR Morbidity Mortality Weekly Rep. 2017;66(36):959–960.
  • Tejada-Strop A, Costafreda M, Dimitrova Z, et al. Evaluation of potencies of immune globulin products against hepatitis A. JAMA Intern Med. 2017;177(3):430–432.
  • Mearkle R, Bologun K, Edelstein M, et al. Public health control and management of hepatitis A. London: Public Health England; 2017.
  • Public health England. Immunoglobulin handbook: hepatitis A. London, United Kingdom: Public Health England; 2017.
  • Hodkinson J. Considerations for dosing immunoglobulin in obese patients. Clin Exp Immunol. 2017;188:363–370.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.